Von Willebrand factor and platelet glycoprotein Ib-IX-V complex interface (VWF-GPIb interface)

The Von Willebrand factor (VWF) and platelet glycoprotein Ib-IX-V (GPIb-IX-V) complex interface is a critical mediator of primary hemostasis, particularly under conditions of high shear stress found in arteries (UniProt P04275; UniProt P07359). VWF is a large, multimeric glycoprotein that, upon vascular injury, undergoes a conformational change to expose its A1 domain, which then binds to the GPIbα subunit of the platelet receptor complex (StatPearls: Von Willebrand Factor). This interaction facilitates the initial tethering and rolling of platelets on the subendothelial matrix, a prerequisite for subsequent stable adhesion and thrombus formation (Journal of Thrombosis and Haemostasis, 2016). Dysregulation of this interface is central to several hematologic and cardiovascular pathologies, including Von Willebrand disease and thrombotic thrombocytopenic purpura (TTP), where excessive activity occurs due to a lack of the ADAMTS13 protease (NIH: Genetics Home Reference). Therapeutic targeting of this interface, such as with the nanobody caplacizumab, aims to prevent pathological platelet aggregation without severely compromising systemic hemostasis (FDA: Cablivi Label). By specifically blocking the VWF-GPIb interaction, these agents offer a targeted approach to treating arterial thrombosis and microangiopathies while potentially carrying a lower risk of major bleeding compared to traditional antiplatelet or anticoagulant therapies (PubMed: PMC6524835).

Other names

VWF-GPIbα axisVWF-GPIb-V-IX interactionPlatelet adhesion interfaceVWF A1-GPIbα complex

Inhibition of the interaction between the Von Willebrand factor A1 domain and the platelet glycoprotein Ib-IX-V complex, thereby preventing platelet tethering and adhesion under high shear stress conditions.